louisiana glp-1 intestinal paralysis law office lawmakers are considering a bill that would expand Medicaid access to drugs for obesity treatment, a move supporters say could improve health outcomes and reduce long-term costs. https://bit.ly/4usEGVI Thousands of patients are suing
Description
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as breakthrough drugsin 2023 and their popularity has soared since. More than 4 million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/20261, while around2.5 million people each monthaccessed GLP-1s privately at the end of 2025, according to James Kingsland, chair of []
GLP-1 medications cause muscle loss, skin laxity, and fatigue
.
As millions quit GLP-1 drugs and weight rebounds faster than expected, food makers face rising pressure around nutrition, trust and mental health.
